ABBV — AbbVie Inc.

NYSE · Health Care · Pharmaceuticals · CIK 1551152 ·
Last close
$253.35
Market Cap
$447.62B
52W High
$253.35
52W Low
$190.75
ADV30
7,485,027
Next earnings
2026-07-31
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Dec 2025 16,618,000,000 12,066,000,000 5,809,000,000 1,816,000,000 133,960,000,000 5,229,000,000 137,188,000,000
Sep 2025 15,776,000,000 10,472,000,000 4,584,000,000 186,000,000 133,898,000,000 5,629,000,000 136,497,000,000
Jun 2025 15,423,000,000 11,077,000,000 5,717,000,000 938,000,000 137,182,000,000 6,467,000,000 137,320,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$19,030,000,000
Investing CF
$-6,643,000,000
Financing CF
$-12,724,000,000
CapEx
$-1,214,000,000
Dividends Paid
$-11,657,000,000
Buybacks
$-980,000,000
EPS Diluted TTM
$2.03
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-15,493,000,000
Inventory
$4,951,000,000
Receivables
$12,589,000,000
ST Investments
$28,000,000
EBIT TTM
$7,129,000,000
Pretax Income TTM
$4,936,000,000
Interest Exp TTM
$2,193,000,000
Analysts
30

Yahoo Snapshot (yfinance, live)

Total Revenue
$62,819,000,320
EBITDA
$29,915,000,832
Free Cash Flow
$20,811,624,448
Enterprise Value
$511,181,946,880
Total Cash
$9,390,999,552
Total Debt
$72,912,003,072
Shares Out
1,766,792,821
Trailing EPS
$2.05
Book Value
$-3.77
ROE
ROA
10.0%
Div Yield
2.73%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 61,160,000,000 20,091,000,000 4,226,000,000 133,960,000,000 137,188,000,000 19,030,000,000
Dec 2024 56,334,000,000 11,894,000,000 4,278,000,000 135,161,000,000 131,797,000,000 18,806,000,000
Dec 2023 54,318,000,000 13,535,000,000 4,863,000,000 134,711,000,000 124,314,000,000 22,839,000,000
Dec 2022 58,054,000,000 18,814,000,000 11,836,000,000 138,805,000,000 121,518,000,000 24,943,000,000

TTM Snapshot

Revenues TTM
$57,541,000,000
NetIncome TTM
$10,467,000,000
OpCashFlow TTM
$0
Assets (Latest)
$135,161,000,000
Forward EPS
$16.29

Max Pain — expiry 2026-07-02

max pain strike: $227.50 · spot: $254.77 · call oi: 6,399 · put oi: 2,702
Expected Move to 2026-07-02: ±$6.09 (2.39%) — implied range $248.68$260.87 · ATM straddle on $255.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
JNJ JOHNSON & JOHNSON $613.02B $254.66
MRK Merck & Co., Inc. $317.77B $128.66
NVS NOVARTIS AG $296.54B $155.41
NVSEF NOVARTIS AG $292.66B $153.38
AZN ASTRAZENECA PLC $292.20B $188.41

News headlines (Yahoo Finance, 1h cache)

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
2026-06-29 15:41 · Yahoo
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
2026-06-29 14:19 · Yahoo
2 S&P 500 Stocks with Promising Prospects and 1 We Find Risky
2026-06-29 14:02 · Yahoo
Here's Why Shares of Eli Lilly Hit an All-Time High on Friday
2026-06-29 13:27 · Yahoo
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
2026-06-29 11:05 · Yahoo
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
2026-06-29 07:10 · Yahoo
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
2026-06-29 07:00 · Yahoo
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why
2026-06-28 14:01 · Yahoo
AbbVie (ABBV) Wins Health Canada Approval for Boey
2026-06-28 00:07 · Yahoo
AbbVie (ABBV) to Acquire Apogee Therapeutics
2026-06-27 19:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.